CoChat

Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression

Open access
Hieronymus, F, Lisinski, A, Nilsson, S, Eriksson, E · 2018 · Molecular Psychiatry
Cited by 44

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

It has been suggested that the superiority of antidepressants over placebo in controlled trials is merely a consequence of side effects enhancing the expectation of improvement by making the patient realize that he/she is not on placebo. We explored this hypothesis in a patient-level post hoc-analysis including all industry-sponsored, Food and Drug Administration-registered placebo-controlled trials of citalopram or paroxetine in adult major depression that used the Hamilton Depression Rating Scale (HDRS) and included a week 6 symptom assessment (n=15). The primary analyses, which compared completers on active treatment without early adverse events to completers on placebo (with or without adverse events) with respect to reduction in the HDRS depressed mood item showed larger symptom reduction in patients given active treatment, the effect sizes being 0.48 for citalopram and 0.33 for paroxetine. In actively treated subjects reporting early adverse events, who also outperformed those given placebo, the severity of the adverse events did not predict response. Several sensitivity analyses, for example, including (i) those using change of the sum of all HDRS-17 items as effect parameter, (ii) those excluding all subjects with adverse events (that is, also those on placebo) and (iii) those based on the intention-to-treat population, were all in line with the primary analyses. The finding that both paroxetine and citalopram are clearly superior to placebo also when not producing adverse events, as well as the lack of association between adverse event severity and response, argue against the theory that antidepressants outperform placebo solely or largely because of their side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mp.2017.147

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 26

  1. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevent Treat 1998; 1, Article 2a. · DOI · Paper page
  2. Moncrieff J. Are antidepressants as effective as claimed? No, they are not effective at all. Can J Psychiatry 2007; 52: 96–97. · DOI
  3. Kirsch I. The emperor's new drugs: medication and placebo in the treatment of depression. Handb Exp Pharmacol 2014; 225: 291–303. · DOI
  4. Moncrieff J. Antidepressants: misnamed and misrepresented. World Psychiatry 2015; 14: 302–303. · DOI · Paper page
  5. Kirsch I. The Emperor's New Drugs: Exploding The Antidepressant Myth. Basic Books: New York, NY, 2010.
  6. Angell M. The Epidemic of Mental Illness: Why? New York Review of Books. June 23, 2011. Available at http://www.nybooks.com/articles/2011/06/23/epidemic-mental-illness-why/ . Accessed on 3 March 2017.
  7. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182: 547–551. · DOI · Paper page
  8. Barth M, Kriston L, Klostermann S, Barbui C, Cipriani A, Linde K. Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Br J Psychiatry 2016; 208: 114–119. · DOI · Paper page
  9. Rabinowitz J, Werbeloff N, Mandel FS, Menard F, Marangell L, Kapur S. Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry 2016; 209: 427–428. · DOI · Paper page
  10. Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2016; 21: 523–530. · DOI · Paper page
  11. Nilsson ME, Koke SC. Defining treatment-emergent adverse events with the medical dictionary for regulatory activities (MedDRA). Drug Inf J 2001; 35: 1289–1299. · doi:10.1177/009286150103500425
  12. Letemendia FJ, Harris AD. The influence of side-effects on the reporting of symptoms. Psychopharmacologia 1959; 1: 39–47. · doi:10.1007/bf00408110
  13. Rabkin JG, Markowitz JS, Stewart J, McGrath P, Harrison W, Quitkin FM et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 1986; 19: 75–86. · DOI
  14. Petkova E, Quitkin FM, McGrath PJ, Stewart JW, Klein DF. A method to quantify rater bias in antidepressant trials. Neuropsychopharmacology 2000; 22: 559–565. · DOI
  15. Liberman R. A criticism of drug therapy in psychiatry. Arch Gen Psychiatry 1961; 4: 131–136. · doi:10.1001/archpsyc.1961.01710080027005
  16. Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965; 17: 101–141. · DOI · Paper page
  17. Thomson R. Side effects and placebo amplification. Br J Psychiatry 1982; 140: 64–68. · DOI · Paper page
  18. Anderson IM. Antidepressant quandaries (letter). Br J Psychiatry 1998; 173: 181–182. · doi:10.1192/bjp.173.2.181b
  19. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. Am J Psychiatry 2000; 157: 327–337. · DOI · Paper page
  20. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958; 115: 459–464. · DOI · Paper page
  21. Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15: 1563–1586. · DOI · Paper page
  22. Scott AI, Perini AF, Shering PA, Whalley LJ. In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 1991; 40: 127–129. · DOI
  23. Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol Ser 1993; 10: 190–198.
  24. Ansseau M, Darimont P, Lecoq A, De Nayer A, Evrad JL, Krémer P et al. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 1994; 115: 254–260. · doi:10.1007/bf02244780
  25. Lapierre YD, Browne M, Oyewumi K, Sarantidis D. Alprazolam and amitriptyline in the treatment of moderate depression. Int Clin Psychopharmacol 1994; 9: 41–45. · DOI
  26. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007; 29: 2319–2332. · DOI

Cited by

Metadata

Authors
Hieronymus, F., Lisinski, A., Nilsson, S., & Eriksson, E.
Venue
Molecular Psychiatry
Published
2017-07-25
Volume
23
Issue
8
Pages
1731-1736
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2738633407
Cited by
44
References
5
FWCI
2.78
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-nd/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.